A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
Clinical trial NCT04686136 · COMPLETED
Trial details
- NCT number
- NCT04686136
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-19
- Primary completion
- 2025-10-20
- Enrollment
- 596
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.